CMRX Stock Overview

A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. More details

CMRX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 93.6% below our estimate of its fair value

Earnings are forecast to grow 52.4% per year

Earnings have grown 20.7% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($159K)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Chimerix, Inc. Competitors

CureVac

NasdaqGM:CVAC

US$675.2m

Arbutus Biopharma

NasdaqGS:ABUS

US$625.3m

Arcus Biosciences

NYSE:RCUS

US$988.5m

Prothena

NasdaqGS:PRTA

US$739.6m

Price History & Performance

Summary of share price highs, lows and changes for Chimerix
Historical stock prices
Current Share Price	US$8.46
52 Week High	US$8.48
52 Week Low	US$0.75
Beta	0.32
1 Month Change	93.15%
3 Month Change	190.72%
1 Year Change	635.65%
3 Year Change	59.62%
5 Year Change	555.81%
Change since IPO	-54.98%

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Feb 20

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11

Recent updates

Shareholder Returns

	CMRX	US Biotechs	US Market
7D	0.4%	-0.9%	-2.2%
1Y	635.7%	-5.0%	9.6%

Return vs Industry: CMRX exceeded the US Biotechs industry which returned -5% over the past year.

Return vs Market: CMRX exceeded the US Market which returned 9.6% over the past year.

Price Volatility

Is CMRX's price volatile compared to industry and market?
CMRX volatility
CMRX Average Weekly Movement	22.2%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.4%

Stable Share Price: CMRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CMRX's weekly volatility has decreased from 34% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2000	72	Mike Andriole	www.chimerix.com

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Chimerix, Inc. Fundamentals Summary

How do Chimerix's earnings and revenue compare to its market cap?
CMRX fundamental statistics
Market cap	US$760.86m
Earnings (TTM)	-US$83.59m
Revenue (TTM)	US$159.00k

4,785x

P/S Ratio

-9.1x

P/E Ratio

Is CMRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMRX income statement (TTM)
Revenue	US$159.00k
Cost of Revenue	US$73.55m
Gross Profit	-US$73.39m
Other Expenses	US$10.21m
Earnings	-US$83.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.93
Gross Margin	-46,154.72%
Net Profit Margin	-52,574.84%
Debt/Equity Ratio	0%

How did CMRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/16 01:38
End of Day Share Price	2025/03/14 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Geoffrey Meacham	Barclays
Jonathan Aschoff	Brean Capital
Ritu Baral	Canaccord Genuity

CMRX Stock Overview

Rewards

Risk Analysis

Chimerix, Inc. Competitors

NasdaqGM:CVAC

US$675.2m

NasdaqGS:ABUS

US$625.3m

NYSE:RCUS

US$988.5m

NasdaqGS:PRTA

US$739.6m

Price History & Performance

Recent News & Updates

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Recent updates

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven